U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Advanced Dedifferentiated Liposarcoma

MedGen UID:
1718832
•Concept ID:
C5239069
•
Neoplastic Process

Definition

A dedifferentiated liposarcoma that has spread extensively to other anatomic sites or is no longer responding to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAdvanced Dedifferentiated Liposarcoma

Professional guidelines

PubMed

Diagnosis and Treatment of Myxoid Liposarcoma.
Qu G, Zhang C, Tian Z, Yao W
Curr Treat Options Oncol 2024 Oct;25(10):1289-1296. Epub 2024 Sep 20 doi: 10.1007/s11864-024-01262-9. PMID: 39302575
Myxoid Liposarcomas: Systemic Treatment Options.
Nassif EF, Keung EZ, Thirasastr P, Somaiah N
Curr Treat Options Oncol 2023 Apr;24(4):274-291. Epub 2023 Feb 28 doi: 10.1007/s11864-023-01057-4. PMID: 36853469
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat 2022;45(9):525-543. Epub 2022 May 24 doi: 10.1159/000524939. PMID: 35609512

Recent clinical studies

Etiology

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
Movva S, Matloob S, Handorf EA, Choy E, Merriam P, Flieder DB, Cai KQ, Zhou Y, Tetzlaff ED, Pagan C, Barker E, Veggeberg R, Zumpano D, Rink L, von Mehren M, George S
Clin Cancer Res 2024 Jan 17;30(2):315-322. doi: 10.1158/1078-0432.CCR-23-2469. PMID: 37967116
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
Sanfilippo R, Hayward RL, Musoro J, Benson C, Leahy MG, Brunello A, Blay JY, Steeghs N, Desar IME, Ali N, Hervieu A, Thway K, Marreaud S, Litiere S, Kasper B
JAMA Oncol 2022 Oct 1;8(10):1420-1425. doi: 10.1001/jamaoncol.2022.3218. PMID: 35980618Free PMC Article

Diagnosis

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
Sanfilippo R, Hayward RL, Musoro J, Benson C, Leahy MG, Brunello A, Blay JY, Steeghs N, Desar IME, Ali N, Hervieu A, Thway K, Marreaud S, Litiere S, Kasper B
JAMA Oncol 2022 Oct 1;8(10):1420-1425. doi: 10.1001/jamaoncol.2022.3218. PMID: 35980618Free PMC Article
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S
Future Oncol 2021 Aug;17(22):2923-2939. Epub 2021 Apr 15 doi: 10.2217/fon-2021-0284. PMID: 33855868Free PMC Article

Therapy

A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma.
Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N
Nat Cancer 2024 Apr;5(4):625-641. Epub 2024 Feb 13 doi: 10.1038/s43018-024-00726-z. PMID: 38351182
SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
Movva S, Matloob S, Handorf EA, Choy E, Merriam P, Flieder DB, Cai KQ, Zhou Y, Tetzlaff ED, Pagan C, Barker E, Veggeberg R, Zumpano D, Rink L, von Mehren M, George S
Clin Cancer Res 2024 Jan 17;30(2):315-322. doi: 10.1158/1078-0432.CCR-23-2469. PMID: 37967116
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J, Martinez-Garcia J, Moura DS, Redondo A, Gutierrez A, Lopez-Pousa A, Martinez-Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez MP, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N
Signal Transduct Target Ther 2023 Oct 25;8(1):405. doi: 10.1038/s41392-023-01661-8. PMID: 37875500Free PMC Article
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma: A Phase 2 Study of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
Sanfilippo R, Hayward RL, Musoro J, Benson C, Leahy MG, Brunello A, Blay JY, Steeghs N, Desar IME, Ali N, Hervieu A, Thway K, Marreaud S, Litiere S, Kasper B
JAMA Oncol 2022 Oct 1;8(10):1420-1425. doi: 10.1001/jamaoncol.2022.3218. PMID: 35980618Free PMC Article
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S
Future Oncol 2021 Aug;17(22):2923-2939. Epub 2021 Apr 15 doi: 10.2217/fon-2021-0284. PMID: 33855868Free PMC Article

Prognosis

Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J, Martinez-Garcia J, Moura DS, Redondo A, Gutierrez A, Lopez-Pousa A, Martinez-Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez MP, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N
Signal Transduct Target Ther 2023 Oct 25;8(1):405. doi: 10.1038/s41392-023-01661-8. PMID: 37875500Free PMC Article

Clinical prediction guides

SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
Movva S, Matloob S, Handorf EA, Choy E, Merriam P, Flieder DB, Cai KQ, Zhou Y, Tetzlaff ED, Pagan C, Barker E, Veggeberg R, Zumpano D, Rink L, von Mehren M, George S
Clin Cancer Res 2024 Jan 17;30(2):315-322. doi: 10.1158/1078-0432.CCR-23-2469. PMID: 37967116
Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J, Martinez-Garcia J, Moura DS, Redondo A, Gutierrez A, Lopez-Pousa A, Martinez-Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez MP, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N
Signal Transduct Target Ther 2023 Oct 25;8(1):405. doi: 10.1038/s41392-023-01661-8. PMID: 37875500Free PMC Article
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Gounder M, Abdul Razak AR, Gilligan AM, Leong H, Ma X, Somaiah N, Chawla SP, Martin-Broto J, Grignani G, Schuetze SM, Vincenzi B, Wagner AJ, Chmielowski B, Jones RL, Shah J, Shacham S, Kauffman M, Riedel RF, Attia S
Future Oncol 2021 Aug;17(22):2923-2939. Epub 2021 Apr 15 doi: 10.2217/fon-2021-0284. PMID: 33855868Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...